A single injection of a new COVID-19 antiviral treatment cut the risk of hospitalization for infection in half in clinical trials

Phase 3, randomized control trial (n=24,966) for single dose RSV vaccine (RSVPreF3 OA) was shown to be highly efficacious against severe disease and infection in older adults (60+) regardless of RSV subtype

A bivalent mRNA vaccine targeting omicron BA.4–BA.5 sublineages resulted in neutralization of other SARS-CoV-2 variants similar to that of a fourth dose of a monovalent mRNA vaccine.

Results from a study showed that a computerized simulated-driving program improved ADHD teen driving by reducing the rate of collisions/near-collisions post-training

Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression | NEJM

Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death

Milestone: Tofersen reverses ALS weakness in some cases.

The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns.

A Zoonotic Henipavirus in Febrile Patients in China | NEJM